Clinical Trial Update: Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) [Phase 3]

View source ↗

Summary

Phase 3 crossover trial evaluating UX007 for movement disorders in Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucose Transporter Type Deficiency Syndrome

Drugs mentioned

• UX007 (triheptanoin)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Phase 3 | Status: TERMINATED | Results posted: 2020-04-24